Federal Circuit dismisses Amgen’s Neulasta appeal

California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Amgen settles with Coherus over arthritis treatment

28 November 2019 Amgen and Coherus Biosciences have settled a patent infringement dispute, after Coherus claimed that Amgen was infringing three of its patents.

Americas

Coherus attempts to dismiss Amgen’s Neulasta suit

12 June 2017 Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.

Americas

Amgen sets sights on Coherus over biologic drug

12 May 2017 Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Federal Circuit dismisses Amgen’s Neulasta appeal

More on this story

Editor's picks

Editor's picks

More features